This retrospective multicenter case-series evaluated eosinophilic fasciitis (EF) induced by immune checkpoint inhibitors (ICIs), comparing clinical features, management, and outcomes with EF unrelated to checkpoint inhibition, alongside a literature review.
ICI-induced EF was identified as a distinct immune-related adverse event; specific differences in presentation, lab findings, and treatment response were noted compared to idiopathic EF, though exact case numbers and outcome metrics are not available from the abstract alone.
Retrospective design limits causal inference; multicenter case-series with likely small sample size introduces selection bias; comparison group characteristics and follow-up duration are not fully specified from available data.
Clinicians should consider EF as a potential immune-related adverse event in patients on checkpoint inhibitors who present with skin induration and eosinophilia. Early recognition and comparison with idiopathic EF may guide timely immunosuppressive treatment.
Explore related topics
